文献速递心脑血管急症复苏、休克与脓毒症重症综合管理与镇静镇痛

特利加压素在实验性急性肺栓塞中升高体循环动脉压并降低肺动脉压

Terlipressin Increases Systemic and Lowers Pulmonary Arterial Pressure in Experimental Acute Pulmonary Embolism.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论猪急性肺栓塞模型中,特利加压素产生体循环血管收缩和肺血管舒张,但心输出量下降、乳酸升高,原文结论不提示常规用于急性肺栓塞。

该研究在12头雌性猪(约60 kg)中经三次自体大血栓诱导急性肺栓塞,随后分别给予特利加压素(n=6)或溶媒(n=6)四个递增剂量,通过有创血流动力学、经食管超声和血液分析评估体内效应,并离体用肌张力仪评估肺动脉。肺栓塞使肺血管阻力较基线升高四倍(p<0.0001)、平均肺动脉压较基线升高两倍(p<0.0001)。与溶媒相比,特利加压素使平均体循环动脉压升高28±5 mm Hg(p<0.0001)、体循环血管阻力升高1,320±143 dynes(p<0.0001),使平均肺动脉压降低6.5±1.8 mm Hg(p=0.005),肺血管阻力有下降趋势(-83±33 dynes;p=0.07)。特利加压素使心输出量下降2.5±0.5 L/min(p<0.0001)、血浆乳酸升高2.7±0.2 mmol/L(p<0.0001),S100b未变(0.17±0.11 µg/L;p=0.51);离体实验中特利加压素舒张肺动脉、收缩肠系膜动脉。作者结论认为这些发现需谨慎转化到临床,不提示急性肺栓塞中常规使用。

要点

  • 猪急性肺栓塞模型中,特利加压素较溶媒使平均体循环动脉压升高28±5 mm Hg(p<0.0001)、体循环血管阻力升高1,320±143 dynes(p<0.0001)。
  • 同一模型中,特利加压素较溶媒使平均肺动脉压降低6.5±1.8 mm Hg(p=0.005),肺血管阻力有下降趋势(-83±33 dynes;p=0.07)。
  • 特利加压素使心输出量下降2.5±0.5 L/min(p<0.0001)、血浆乳酸升高2.7±0.2 mmol/L(p<0.0001),可能提示全身灌注不足。
  • 脑缺血标志物S100b未变(0.17±0.11 µg/L;p=0.51),提示脑灌注保留。
  • 离体实验中特利加压素舒张肺动脉、收缩肠系膜动脉;作者结论不提示急性肺栓塞中常规使用特利加压素。

适用人群与场景

  • 雌性猪(Land Race、Duroc与Yorkshire杂交,约60 kg,n=12)经三次大型自体血栓诱导的急性肺栓塞模型。

处置流程与药物剂量

  • 动物随机接受特利加压素(n=6)或溶媒(n=6)四个递增剂量;原文未写明特利加压素的具体剂量、单位和给药途径。

研究设计与关键结果

  • 研究类型为对照动物实验,12头雌性猪,特利加压素组n=6、溶媒组n=6,四个递增剂量。
  • 肺栓塞后肺血管阻力较基线升高四倍(p<0.0001),平均肺动脉压较基线升高两倍(p<0.0001)。
  • 与溶媒相比,特利加压素使平均体循环动脉压升高28±5 mm Hg(p<0.0001)、体循环血管阻力升高1,320±143 dynes(p<0.0001)。
  • 与溶媒相比,特利加压素使平均肺动脉压降低6.5±1.8 mm Hg(p=0.005),肺血管阻力有下降趋势(-83±33 dynes;p=0.07)。
  • 特利加压素使心输出量下降2.5±0.5 L/min(p<0.0001)、血浆乳酸升高2.7±0.2 mmol/L(p<0.0001)。
  • S100b未变(0.17±0.11 µg/L;p=0.51);离体实验中特利加压素舒张肺动脉、收缩肠系膜动脉。

证据类型、等级与局限

  • 证据类型:对照动物实验(猪急性肺栓塞模型)。
  • 作者结论:特利加压素产生体循环血管收缩和肺血管舒张,但心输出量下降、乳酸升高可能主要因其体循环血管收缩效应;这些发现需谨慎转化到临床,不提示急性肺栓塞中常规使用。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论不提示在急性肺栓塞中常规使用特利加压素。
  • 作者认为这些发现应谨慎转化到临床。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: We investigated whether the vasopressin-analog, terlipressin induces systemic vasoconstriction and pulmonary vasodilation in a porcine model of acute pulmonary embolism.

DESIGN: Controlled, animal study.

SETTING: Tertiary medical center research laboratory.

SUBJECTS: Female pigs (n = 12, Cross of Land Race, Duroc, and Yorkshire ~ 60 kg).

INTERVENTIONS: Acute pulmonary embolism was induced by administration of three large autologous emboli. Animals then received four increasing doses of either terlipressin (n = 6) or vehicle (n = 6).

MEASUREMENTS AND MAIN RESULTS: Effects were evaluated in vivo at baseline, after pulmonary embolism and after each dose by invasive hemodynamic measures, transesophageal echocardiography, and blood analysis. Isolated pulmonary arteries were evaluated ex vivo in a myograph. Pulmonary embolism caused a four-fold increase in pulmonary vascular resistance (p < 0.0001) and a two-fold increase in mean pulmonary arterial pressure (p < 0.0001) compared with baseline. Terlipressin increased mean systemic blood pressure (28 ± 5 mm Hg; p < 0.0001) and systemic vascular resistance (1,320 ± 143 dynes; p < 0.0001) compared with vehicle. In the pulmonary circulation, terlipressin decreased mean pulmonary arterial pressure (-6.5 ± 1.8 mm Hg; p = 0.005) and tended to decrease pulmonary vascular resistance (-83 ± 33 dynes; p = 0.07). Terlipressin decreased cardiac output (-2.5 ± 0.5 L/min; p < 0.0001) and increased plasma lactate (2.7 ± 0.2 mmol/L; p < 0.0001), possibly indicating systemic hypoperfusion. A biomarker of cerebral ischemia, S100b, remained unchanged, suggesting preserved cerebral perfusion (0.17 ± 0.11 µg/L; p = 0.51). Ex vivo, terlipressin relaxed pulmonary and constricted mesenteric arteries.

CONCLUSIONS: Terlipressin caused systemic vasoconstriction and pulmonary vasodilation in a porcine in vivo model of acute pulmonary embolism and vasorelaxation in isolated pulmonary arteries. Despite positive vascular effects, cardiac output declined and plasma lactate increased probably due to a predominantly systemic vasoconstrictor effect of terlipressin. These findings should warrant careful translation to the clinical setting and does not suggest routine use in acute pulmonary embolism.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Schultz J, Andersen A, Lyhne MD, et al. Terlipressin Increases Systemic and Lowers Pulmonary Arterial Pressure in Experimental Acute Pulmonary Embolism. Crit Care Med. 2020. PMID: 32205621. doi:10.1097/CCM.0000000000004243

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。